CLINICAL TRIALS PROFILE FOR INVEGA
✉ Email this page to a colleague
All Clinical Trials for Invega
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00330863 ↗ | Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2006-05-01 | This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms. |
| NCT00330863 ↗ | Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy | Completed | Northwell Health | Phase 4 | 2006-05-01 | This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms. |
| NCT00488891 ↗ | The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia | Terminated | Ortho-McNeil Janssen Scientific Affairs, LLC | 2007-04-01 | The purpose of this study is to examine the long-term economic, functional and clinical outcomes in schizophrenia patients who require a change in antipsychotic treatment, and are changed to either paliperidone extended release (ER) or another oral atypical antipsychotic agent (AAP) including aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone. | |
| NCT00549562 ↗ | Study of Paliperidone ER in Adolescents and Young Adults With Autism | Completed | Ortho-McNeil Janssen Scientific Affairs, LLC | Phase 3 | 2007-11-01 | This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults. |
| NCT00549562 ↗ | Study of Paliperidone ER in Adolescents and Young Adults With Autism | Completed | Indiana University School of Medicine | Phase 3 | 2007-11-01 | This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults. |
| NCT00566631 ↗ | An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia | Completed | Janssen-Cilag International NV | Phase 3 | 2007-07-01 | The purpose of this study is to evaluate the tolerability, safety and treatment response of flexible doses of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with acute schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). |
| NCT00592358 ↗ | Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder | Terminated | Massachusetts General Hospital | Phase 4 | 2007-11-01 | This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. Specific hypotheses are as follows: Hypothesis 1: Bipolar Disorder symptomatology in children and adolescents with DSM-IV Bipolar I, Bipolar II, or Bipolar Spectrum Disorder will be responsive to Invega treatment. Hypothesis 2: Invega -associated improvement in bipolar disorder symptomatology in children and adolescents will translate into improved functional capacities (neuropsychological, social, and occupational), as well as an increased quality of life throughout treatment. Hypothesis 2: Invega treatment will be safe and well tolerated as reflected by a low drop out rate and absence of major side effects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Invega
Condition Name
Clinical Trial Locations for Invega
Trials by Country
Clinical Trial Progress for Invega
Clinical Trial Phase
Clinical Trial Sponsors for Invega
Sponsor Name
